Myriad Explores NGS Platforms but Cost, Accuracy, and Speed Don't Yet Satisfy Needs for BRCA Testing | GenomeWeb

As several European diagnostics labs have ported BRCA1 and BRCA2 testing to next-generation sequencing, Myriad Genetics has not yet found a platform that satisfies its needs for BRACAnalysis, its most important test today.

"We are continuously looking [at new technologies] to potentially upgrade our platform, when the technology gets to a point where it is cost-effective, has high enough accuracy, and can provide a turnaround time that is within our standards," a company spokesperson told Clinical Sequencing News.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.